One Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and Meta-analysis.

Abstract

This systematic review and meta-analysis concludes that the PreserFlo Microshunt glaucoma drainage device significantly reduces intraocular pressure in primary open-angle glaucoma patients at 12 months post insertion. A systematic review and meta-analysis on the effect of the PRESERFLO™ MicroShunt (PF-MS) on intraocular pressure (IOP) at 12 months has been conducted. The Pubmed/MEDLINE, Embase, CENTRAL, Google Scholar, Scopus and Web of Science databases were searched. Inclusion criteria required a diagnosis of open-angle glaucoma, PF-MS insertion, and examination of IOP over time. Meta-analyses were conducted on the primary outcome of IOP and the secondary outcome of glaucoma medication regime. Adverse events were also noted. Fourteen studies were identified for inclusion in the meta-analyses, of which none had a high risk of bias. The meta-analyses found a significant mean reduction in IOP of 9.07mmHg (95% CI 7.88 - 10.25; P<0.0001) and a significant mean reduction in mean glaucoma medication requirement of 2.37 medications (95% CI 2.15 - 2.60); P<0.0001). Hypotony and hyphaema are common early complications. The PF-MS device significantly reduced both IOP and glaucoma medication requirement at 12 months post insertion in individuals with open-angle glaucoma without a significant adverse event burden. Further research is required to determine the economic and environmental effects of widely implementing the PF-MS device into clinical practice.